Infectious Disease / Microbiology Updates
Open in Telegram
All the atest articles, research and news from worlds leading Infectious Disease Journals. Discussion group https://t.me/Professional_Medical_Discussion
Show more7 558
Subscribers
+424 hours
+647 days
+30730 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
July '26
July '26
+278
in 0 channels
June '26
+282
in 0 channels
Get PRO
May '26
+332
in 0 channels
Get PRO
April '26
+290
in 0 channels
Get PRO
March '26
+159
in 0 channels
Get PRO
February '26
+244
in 0 channels
Get PRO
January '26
+245
in 0 channels
Get PRO
December '25
+204
in 0 channels
Get PRO
November '25
+247
in 2 channels
Get PRO
October '25
+81
in 1 channels
Get PRO
September '25
+17
in 0 channels
Get PRO
August '25
+25
in 0 channels
Get PRO
July '25
+31
in 1 channels
Get PRO
June '25
+18
in 0 channels
Get PRO
May '25
+17
in 0 channels
Get PRO
April '25
+37
in 0 channels
Get PRO
March '25
+30
in 0 channels
Get PRO
February '25
+12
in 0 channels
Get PRO
January '25
+26
in 2 channels
Get PRO
December '24
+107
in 0 channels
Get PRO
November '24
+450
in 0 channels
Get PRO
October '24
+436
in 0 channels
Get PRO
September '24
+389
in 1 channels
Get PRO
August '24
+297
in 0 channels
Get PRO
July '24
+532
in 3 channels
Get PRO
June '240
in 0 channels
Get PRO
May '24
+77
in 1 channels
Get PRO
April '24
+141
in 0 channels
Get PRO
March '24
+162
in 0 channels
Get PRO
February '24
+187
in 0 channels
Get PRO
January '24
+293
in 0 channels
Get PRO
December '23
+319
in 0 channels
Get PRO
November '23
+156
in 0 channels
Get PRO
October '23
+260
in 1 channels
Get PRO
September '23
+167
in 0 channels
Get PRO
August '23
+91
in 0 channels
Get PRO
July '23
+85
in 0 channels
Get PRO
June '23
+93
in 0 channels
Get PRO
May '23
+80
in 0 channels
Get PRO
April '23
+88
in 0 channels
Get PRO
March '23
+103
in 0 channels
Get PRO
February '23
+74
in 0 channels
Get PRO
January '23
+90
in 0 channels
Get PRO
December '22
+89
in 0 channels
Get PRO
November '22
+227
in 0 channels
Get PRO
October '22
+75
in 0 channels
Get PRO
September '22
+134
in 0 channels
Get PRO
August '22
+90
in 0 channels
Get PRO
July '22
+65
in 0 channels
Get PRO
June '22
+126
in 0 channels
Get PRO
May '22
+118
in 0 channels
Get PRO
April '22
+75
in 0 channels
Get PRO
March '22
+59
in 0 channels
Get PRO
February '22
+33
in 0 channels
Get PRO
January '22
+46
in 0 channels
Get PRO
December '21
+47
in 0 channels
Get PRO
November '21
+37
in 0 channels
Get PRO
October '21
+59
in 0 channels
Get PRO
September '21
+52
in 0 channels
Get PRO
August '21
+65
in 0 channels
Get PRO
July '21
+68
in 0 channels
Get PRO
June '21
+77
in 0 channels
Get PRO
May '21
+57
in 0 channels
Get PRO
April '21
+190
in 0 channels
Get PRO
March '21
+166
in 0 channels
Get PRO
February '21
+36
in 0 channels
Get PRO
January '21
+35
in 0 channels
Get PRO
December '20
+495
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 24 July | +15 | |||
| 23 July | +6 | |||
| 22 July | +6 | |||
| 21 July | +12 | |||
| 20 July | +14 | |||
| 19 July | +12 | |||
| 18 July | +8 | |||
| 17 July | +14 | |||
| 16 July | +18 | |||
| 15 July | +9 | |||
| 14 July | +11 | |||
| 13 July | +17 | |||
| 12 July | +13 | |||
| 11 July | +13 | |||
| 10 July | +14 | |||
| 09 July | +9 | |||
| 08 July | +7 | |||
| 07 July | +15 | |||
| 06 July | +11 | |||
| 05 July | +5 | |||
| 04 July | +15 | |||
| 03 July | +15 | |||
| 02 July | +9 | |||
| 01 July | +10 |
Channel Posts
Genomic and Epidemiologic Insights into Ongoing Measles Outbreak, Israel, 2025â2026
https://wwwnc.cdc.gov/eid/article/32/9/26-0625_article
| 2 | In the Literature
https://academic.oup.com/cid/article/83/1/ii/8740462?rss=1 | 333 |
| 3 | State-of-the-Art Review: Infections in Patients With Cerebrospinal Fluid Shunts
https://academic.oup.com/cid/article/83/1/1/8740512?rss=1 | 318 |
| 4 | [Correspondence] Keep antibiotics habitable: stewardship as climate mitigation
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00109-X/fulltext?rss=yes
Friends and family kept asking, âWhy infectious diseases?â Although their intent was kind, the subtext was constant: why choose a path that is demanding, less lucrative, and often unseen? I had no slogan in response. I only knew that, since adolescence, I was drawn to infections caused by improbable microorganisms, with protean presentations and diagnostic challenges that leave no room for shortcuts. At first, microorganisms appear as unidentifiable, surreal shapes, until diagnostics and microbiology allow for their identification and characterisation. | 390 |
| 5 | [Correspondence] 25 years of antibiotics: from desperate access to precision safety
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00112-X/fulltext?rss=yes
As The Lancet Infectious Diseases approaches its 25-year anniversary, your Editorial1âand its call for stories of success, hope, and inspirationâresonated strongly with our team. In our intensive care unit (ICU), one such story began with an uncomfortable series of questions at the bedside: âWill tigecycline work?â, âCan we keep this patient safe while it works?â, and âDo we have any other options?â | 355 |
| 6 | [Correspondence] The limb-saving power of bedside Gram staining
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00107-6/fulltext?rss=yes
As infectious disease physicians, we rarely have a single dramatic procedure that instantaneously changes a patient's trajectory: no emergent catheterisation for acute myocardial infarction, no urgent endoscopy for torrential upper gastrointestinal bleeding. Antibiotics can look deceptively simpleâsomething any competent generalist can prescribe. Our value often appears only later, after the fever has lingered, the tests have failed, and someone finally asks, âWhat are we missing?â Even then, the resolution can feel quiet rather than cinematic. | 323 |
| 7 | [Correspondence] Tuberculosis treatment with early detection
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00082-4/fulltext?rss=yes
Recently, I was working in a densely populated informal settlement in Mumbai, a metropolitan city in India, where tuberculosis was a daily finding in my outpatient department due to the high endemicity. One case, however, stayed with me. | 258 |
| 8 | [Correspondence] Rapid recruitment for a remote long COVID clinical trial
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00070-8/fulltext?rss=yes
There have been few long COVID clinical trials relative to the burden of disease,1 and even fewer have been accessible to people with more severe illness.2 As a person who has had moderate-to-severe long COVID (depending on the day) since 2020, I have long advocated for at-home access to clinical trials.3â5 | 255 |
| 9 | [Newsdesk] Research in brief
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00366-X/fulltext?rss=yes
Reverse-transcription quantitative PCR-based assays for orthoebolaviruses such as Ebola, Sudan, and Bundibugyo viruses are resource intensive and take several hours to provide results, highlighting the need for rapid point-of-care tests. Using previously generated murine monoclonal antibodies specific for orthoebolavirus glycoproteins, researchers in Canada developed a prototype immunochromatographic lateral flow assay to detect glycoproteins from all known orthoebolaviruses. In 10 ΟL of plasma or whole blood, the test detected Ebola, Sudan, and Bundibugyo virus recombinant glycoproteins at amounts of 62¡5 ng or 31¡2 ng. | 222 |
| 10 | [Correspondence] Crossing the regulatory and clinical operational valley in antimicrobial resistance: from a start-up's perspective
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00140-4/fulltext?rss=yes
The milestone that gave me the greatest satisfaction last year was not a headline-grabbing breakthrough, but the quiet alignment of two parallel worlds: regulatory clearance and operational readiness for BWC0977, a novel dual-targeting inhibitor of DNA gyrase and topoisomerase IVâa class that has seen little innovation in decades.1 BWC0977, a broad-spectrum antibacterial clinical candidate, is currently undergoing a phase 1 trial in Australia.2 It demonstrates broad-spectrum activity against the major WHO-published list of bacterial priority pathogens. | 211 |
| 11 | [Newsdesk] Cold-chain vehicles to support vaccination in Ecuador
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00368-3/fulltext?rss=yes
In May, 2026, Ecuador became the first country in Latin America and the Caribbean to procure vaccine-transport vehicles with cold-chain technology. Sanjeet Bagcchi reports. | 196 |
| 12 | [Obituary] Edward Pesanti
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00371-3/fulltext?rss=yes
Respected infectious disease expert, physician, and leader in prison health care died on May 27, 2026, aged 81 years. | 191 |
| 13 | [Profile] Krutika Kuppalliâcontaining infectious disease outbreaks
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00370-1/fulltext?rss=yes
In 2014, Krutika Kuppalli served as Medical Director of a large Ebola Treatment Unit (ETU) in Sierra Leone during the West African Ebola virus disease epidemic (2013â16). âIt was the most challenging but transformative experience of my life. Even 12 years later, I am learning from itâ, says Kuppalli. She is now Associate Professor in the Division of Infectious Diseases and Geographic Medicine at UT Southwestern Medical Center, in Dallas, TX, USA, with a secondary appointment in the Peter OâDonell Jr School of Public Health (OSPH). | 199 |
| 14 | [Profile] Troy Grennanâgetting anal cancer the attention it deserves
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00369-5/fulltext?rss=yes
Growing up on Canada's East Coast, the young Troy Grennan had a gay neighbour who had moved away to experience 'big cityâ life in Toronto. Later when doing his own studies in Toronto, Grennan would volunteer (and later work) at Casey House, a well-known hospice (and now large charity) for those dying from or seriously ill with HIV. He was shocked to find his former neighbour as one of Casey House's patients, and the neighbour sadly died from HIV complications. It was one of many experiences he had at Casey House that left him determined to make a difference for people living with HIV. | 203 |
| 15 | [Correspondence] A defining clinical moment during the COVID-19 pandemic in Nigeria
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00306-3/fulltext?rss=yes
Moments that shape careers in infectious diseases are often rooted in uncertainty but clarified by experience. After passing my part one fellowship examination in internal medicine in May 2019, I remained undecided about whether to pursue a career in nephrology or in infectious diseases. This uncertainty was resolved by the emergence of COVID-19 in Nigeria in February 2020, and the rapid establishment of national response structures, including isolation and treatment centres across federal tertiary hospitals. | 222 |
| 16 | [Correspondence] A new era of hope: the impact of long-acting injectables for individuals ageing with childhood HIV
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00303-8/fulltext?rss=yes
HIV carries an unwarranted stigma especially in perinatal and prepubescent populations.1 Thanks to the introduction of antiretroviral therapy (ART) during pregnancy, the rate of perinatal HIV transmission has decreased from 20â30% to 0¡1â0¡5%.2,3 In 2022, nearly 13â000 people in the US were living with perinatal HIV;4 these patients cannot be forgotten. For this perinatal population, daily medication is both beneficial and emotionally challenging. Daily medication can feel burdensome and overwhelming, leading to non-compliance or discontinuation; risking resistance, viraemia, mental anguish, and resentment. | 238 |
| 17 | [Comment] The Bundibugyo virus disease outbreak: a warning signal for risks to health workers
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00364-6/fulltext?rss=yes
The ongoing outbreak of Ebola virus disease caused by Bundibugyo virus in DR Congo and Uganda is a reminder that epidemic preparedness remains weak, particularly where it matters mostâat the front line. The outbreak was declared a Public Health Emergency of Continental Security and International Concern in May, 2026,1 and at least 1294 confirmed cases, including 362 deaths, have been reported as of June 27, 2026.Beyond the concerning epidemiological trajectory, the disproportionately high incidence of infection among health-care workers is an alarming signal, highlighting persistent vulnerabilities in front-line protection and systems for infection prevention and control. | 270 |
| 18 | [Newsdesk] Trials of medical countermeasures to begin in DR Congo
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00365-8/fulltext?rss=yes
Three drugs for Bundibugyo virus treatment and prevention are set to be tested in DR Congo under a previously established protocol for an adaptive platform trial. Esther Nakkazi reports. | 268 |
| 19 | Surveillance of Ticks and Tickborne Borrelia, Ehrlichia, and Rickettsia spp., Texas, USA, 2014â2021
https://wwwnc.cdc.gov/eid/article/32/8/25-1104_article | 732 |
| 20 | Human Lactococcus garvieae Bloodstream Infection Complicated by Spondylodiscitis, Germany
https://wwwnc.cdc.gov/eid/article/32/8/26-0334_article | 684 |
